Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Notes Payables (2017 - 2025)

Historic Notes Payables for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to $400000.0.

  • Vistagen Therapeutics' Notes Payables changed N/A to $400000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $400000.0, marking a year-over-year change of. This contributed to the annual value of $105000.0 for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q4 2025, Vistagen Therapeutics' Notes Payables is $400000.0.
  • Vistagen Therapeutics' Notes Payables' 5-year high stood at $1.0 million during Q2 2022, with a 5-year trough of $105000.0 in Q1 2023.
  • Over the past 3 years, Vistagen Therapeutics' median Notes Payables value was $715000.0 (recorded in 2022), while the average stood at $638637.5.
  • Over the last 5 years, Vistagen Therapeutics' Notes Payables had its largest YoY gain of 2443.63% in 2023, and its largest YoY loss of 2443.63% in 2023.
  • Over the past 3 years, Vistagen Therapeutics' Notes Payables (Quarter) stood at $419100.0 in 2022, then soared by 87.12% to $784200.0 in 2023, then plummeted by 48.99% to $400000.0 in 2025.
  • Its last three reported values are $400000.0 in Q4 2025, $700000.0 for Q3 2025, and $933000.0 during Q2 2025.